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Abstract
Objective: Aortic valve replacement for bioprosthesis
dysfunction is a procedure involving considerable risk. In
some cases, mortality is high and may contraindicate the
procedure. Minimally invasive transcatheter aortic “valve-
in-valve” implant appears to be an alternative, reducing
morbidity and mortality. The objective is to evaluate aortic
valve-in-valve procedure using Braile Inovare prosthesis.
Methods: The Braile Inovare prosthesis, transcatheter,
expandable balloon, was used in 14 cases. Average
EuroSCORE was 42.9%. All patients had double aortic
bioprosthesis dysfunction. Procedures were performed in a
surgical hybrid environment under echocardiographic and
fluoroscopic guidance. Using left minithoracotomy
prostheses were implanted through the ventricular apex
under high-frequency ventricular pacing. Serial clinical and
echocardiographic controls were performed. Follow-up
ranged 1-30 months.
Results: Correct prosthetic deployment was obtained in
all cases. There was no conversion. There was no operative
mortality. The 30-day mortality was 14.3% (two cases).
Ejection fraction increased significantly after the 7th
postoperative day. Aortic gradient significantly reduced. The
residual aortic regurgitation was not present. There were
no vascular complications or complete atrioventricular block.
Conclusion: The transcatheter “valve-in-valve” procedure
for bioprosthesis dysfunction is safe with low morbidity. This
possibility may change prosthesis choice during the first
aortic valve replacement, favoring bioprostheses.
Descriptors: Cardiopulmonary bypass. Aortic valve
stenosis. Heart catheterization.
Resumo
Introdução: A reoperação para substituição de biopróteses
aórticas com disfunção é procedimento que envolve
considerável risco. Em alguns casos, a mortalidade é elevada
e pode contraindicar o procedimento. O implante
minimamente invasivo “valve-in-valve” transcateter de valva
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aórtica parece ser uma alternativa, reduzindo
morbimortalidade. O objetivo deste estudo foi avaliar esses
implantes utilizando a prótese Braile Inovare.
Métodos: A prótese Braile Inovare, transcateter, balão
expansível foi utilizada em 14 casos. Euroscore médio foi de
42,9%. Todos os pacientes eram portadores de dupla disfunção
de bioprótese aórtica. Os procedimentos foram realizados
em ambiente cirúrgico híbrido, sob controle ecocardiográfico
e fluoroscópico. Por meio de minitoracotomia esquerda, as
próteses foram implantadas através do ápice ventricular, sob
estimulação ventricular de alta frequência. Foram
realizados controles clínicos e ecocardiográficos seriados.
O seguimento variou de 1 a 30 meses.
Resultados: A correta liberação protética foi possível em
todos os casos. Não ocorreu conversão. Não houve
mortalidade operatória. A mortalidade em 30 dias foi de
14,3% (dois casos). A fração de ejeção apresentou aumento
significativo após o 7º pós-operatório e o gradiente aórtico
apresentou redução significativa. A insuficiência aórtica
residual não esteve presente. Não ocorreu complicação
vascular periférica ou bloqueio atrioventricular total.
Conclusões: O implante “valve-in-valve” de valva aórtica
transcateter em biopróteses com disfunção é um
procedimento seguro e com morbimortalidade baixa. Essa
possibilidade poderá alterar a indicação de seleção de prótese
no procedimento inicial, favorecendo próteses biológicas.
Descritores: Ponte cardiopulmonar. Estenose da valva
aórtica. Cateterismo cardíaco.
INTRODUCTION
The degenerative aortic valve calcification is
considered the most common cause of aortic stenosis in
developed countries, the most frequent indication for aortic
valve replacement [1]. Standard treatment consists of valve
replacement with a prosthetic device (biological or
mechanical), with operative mortality around 4% [2]. Despite
these results, there are limitations. Bioprostheses have
limited durability, evolving along with structural
degeneration along with the follow-up and the mechanics
have risks as mechanical dysfunction and thrombosis. In
the event of valve replacement (reoperation), the risk is
higher than expected for the first replacement. Furthermore,
some patients exhibit even higher mortality due to various
morbidities. The combination of risk factors may determine
the contraindications of the procedure in 30% of cases [3].
Recently, several groups have proposed the use of
transcatheter therapy in order to reduce morbidity and
mortality associated with conventional intervention when
applied to high-risk individuals [4,5]. The improvement of
the technique has allowed its application more secure and
with progressive improvement of outcomes [6-8]. Recently,
several groups have proposed the use of transcatheter
technology in degenerated bioprostheses, a procedure
called “valve-in-valve”, but the series is still limited and
require confirmation as to its efficacy, safety and
limitations [9].
In our environment, we developed a balloon-expandable
prosthesis with encouraging initial results, including its
use within degenerated bioprostheses [10,11].
The assessment of clinical results, safety and efficacy
of the procedure performed with this new prosthesis within
bioprosthesis dysfunction is the aim of this study.
METHODS
Patient Selection
Between June 2008 and December 2011, 14 patients from
a single center underwent “valve-in-valve” transcatheter
valve implantation being assessed prospectively, after
signing an informed consent and Ethics Committee approval
(CEP 1116/08).
Patients were selected by a multidisciplinary group. The
selection of patients involved, in addition to
multidisciplinary consultation and the inclusion and
exclusion criteria, consideration of aspects such as high
surgical risk, expectation, quality of life and assessment of
biological fragility. The EuroSCORE and STS score risk
scores were used in order to provide quantitative analysis
of individual risk involved in the procedure.
Patients underwent clinical and laboratory tests,
Abbreviations, acronyms and symbols
EuroScore European System for Cardiac Operative Risk
Evaluation
STS Score Society of Thoracic Surgeons score
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echocardiography, cineangiocoronariography and Doppler
ultrasonography of iliac femoral and carotid systems.
The inclusion and exclusion criteria are listed in another
publication [11]. Patients with bioprosthesis measuring 19
mm in diameter were excluded from the indication due to
high risk of residual gradients, given the extreme reduction
of the valve area.Demographic characteristics and
comorbidities of the patients are listed in Tables 1 and 2.
The prostheses presenting dysfunction were composed
of a variety of manufacturers: 3 Porcine Braile Biomédica, 3
Medtronic Hancock, 2 Biocor and 6 unmarked.
Device and Procedure
The “valve-in-valve’ aortic valve implantation was
performed as previously described techniques [8,11]. All
implants were performed with the aid of a surgical C-shaped
arch (BV Pulsera, Philips Medical, The Netherlands), using
radiolucent surgical table and dimensional Transesophageal
echocardiography (C Envisor HD, Philips Medical, The
Netherlands). Complete equipment for cardiopulmonary
bypass was available in stand-by in all cases (Braile
Biomédica, São José do Rio Preto, SP, Brazil). In all cases
transcatheter balloon-expandable bioprosthesis was used
(Braile Biomedica, São José do Rio Preto, SP, Brazil) in sizes
20 to 24 mm in diameter as the inner diameter of the
bioprosthesis dysfunction, considering a size of about 10%.
Intraoperative transesophageal echocardiographic
controls were performed after valve implantation and
hemodynamic stabilization of the patient, in order to check
the correct functioning of the prosthetic valve, as well as
hemodynamic characteristics. Angiographic controls were
performed only in the event of doubt on echocardiogram in
order to avoid the use of iodinated contrast.
After the procedure, all patients were maintained on
dual antiplatelet therapy protocol using aspirin and
clopidogrel.
Table 1. Demographic characteristics and comorbidities.
Characteristic
Age in years (mean)
Females (n/%)
Systemic Arterial Hypertension (n)
Diabetes (n)
Dyslipidemia (n)
Glomerular filtration rate < 50 mL/min (n/%)
Renal dialysis
Restrictive / obstructive lung disease (n/%)
Pulmonary arterial hypertension (n/%)
Operated during hospitalization for decompensation (n/%)
Atrial fibrillation (n/%)
Functional type - NYHA (n/%)
II
III
IV
Comorbidities
Coronary artery disease (n/%)
Prior cardiovascular surgery (n/%)
Peripheral arterial disease (n/%)
Previous stroke (n/%)
Cancer (n/%)
Porcelain aorta (n/%)
Biological fragility (Frailty) (n/%)
Logistic Euroscore (%) (mean)
STS score (%) (mean)
Peak aortic gradient (mean±standard deviation)
Mean aortic gradient (mean±standard deviation)
Left ventricular ejection fraction (mean±standard deviation)
n=14
69.8
7/50
14/100
8/57.1
9/64.2
10/71.4
0
6/42.8
6/42.8
10/71.4
2/14.2
0
4/28.5
10/71.4
11/78.5
14/100
6/42.8
0/0
1/7.1
0/0
12/85.71
42.9
38.6
58.7±15.3
34.7±8.7
51.0±15.90
NYHA – New York Heart Association
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Follow-up and outcomes
Procedural success was defined as correct implant,
satisfactory hemodynamic profile, the absence of significant
valve or perivalvular leaks and no immediate major
complications.
Patients were followed-up serially in the following
postoperative: 1 day, 7 days, 30 days, 6 months, 12 months,
18 months and 24 months, with clinical and
echocardiographic assessments.
The following outcomes were assessed: all-cause
mortality (operative and 30 days post-discharge); major
cardiovascular events, rehospitalization for prosthetic valve
dysfunction or clinical deterioration; functional class;
stroke, vascular complications, renal failure and bleeding.
Outcomes were assessed according to the
recommendations of the Valve Academic Research
Consortium [12].
Statistical Analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS) version 11. The
confidence level of 0.05 was used as significant. The
comparison between the means used the Friedman test after
verification of normal distribution of values. The mean and
standard error were used to express the analysis, unless
otherwise specified. The Kaplan-Meier curve was used for
survival analysis of appropriate outcomes.
RESULTS
Procedure
All cases were performed at the institution in a hybrid
operating room. The successful valve implantation was
performed in all cases. There were no conversions or
prosthesis migrations.
The average time of implantation was 153.7 ± 42.1
minutes. The mean fluoroscopy time was 13.1 ± 7.5 minutes.
The quantity of contrast medium used was 40.0 ml, while
only the first four cases using contrast. No operative
mortality occurred. There was no need to implant more than
one valve in the same patient. Major vascular complication
was not present. There was permanent pacemaker
implantation. There was no severe or mild stroke. There
was transient fall in platelet count in 5 cases.
We used the following device sizes: 2 of 20 mm, 7 of 22
mm and 5 of 24 mm.
The follow-up ranged from 1 to 33 months.
The surgical variables are listed in Table 2.
Mortality and hospital readmissions
Two patients died within 30 days. During the follow-up
after hospital discharge, there was three deaths: a case of
cardiogenic shock with normal functioning prosthesis, a
case of acute myocardial infarction in patients with coronary
artery disease not previously treatable of surgical or
percutaneous  treatment and one by right heart failure and
severe pulmonary hypertension in a patient with sickle cell
anemia (prosthesis normofunctioning) (Figure 1).
Table 2. Operative variables.
Variable
Successful procedure (n/%)
Conversion to conventional replacement (n/%)
Defibrillation (n/%)
Entry into cardiopulmonary bypass (excluding conversions)
Contrast (mL) (mean)
Fluoroscopy time (min) (mean)
Procedure time (min) (mean±standard deviation)
n=14
14/100
0
0
0
40
13.1
153.8±42.2
Fig. 1 - Kaplan Meyer. survival.
Evento = Event; Sobrevida =Survival; Tempo = Time
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Evolution of functional class
The functional class improved significantly compared
preoperatively at 1, 6 and 12 months (P <0.0001). A
comparison of 1, 6 and 12 months did not show a statistically
significant difference.
Echocardiographic assessment
The hemodynamic result assessed by echocardiography
was satisfactory, with significant reduction of the peak
gradient of 58.7 to 24.9 mmHg in the 1st postoperative day
(P <0.001). The outcome showed that reducing the gradient
was maintained in subsequent studies, with no statistically
significant difference between the gradient obtained after
implantation in the immediate postoperative period. The
gradient also demonstrated a significant reduction of 34.7
mmHg to 12.8 mmHg on the first postoperative day (P <0.001).
The outcome showed the maintenance of that reduction.
The periprosthetic aortic insufficiency in the immediate
postoperative period was not present.
 Ventricular function measured by the left ventricular
ejection fraction using the Simpson method showed
statistically significant improvement from 51% to 55.6%,
on the seventh day postoperatively (P <0.01), sustained
during the follow-up.
The intraoperative variables are listed in Table 2.
DISCUSSION
The valve replacement surgery is the procedure of
choice in patients with aortic valve stenosis or prosthetic
valve dysfunction. In the majority of the population,
intervention has low risk and is able to promote functional
improvement and increase the survival rate when compared
to clinical treatment [2.13]. Nevertheless, a progressively
larger portion of that population has necessitated the
replacement of dysfunctional prosthesis and, consequently,
higher operative risk [14].
Within this context, the possibility of less invasive
intervention through transcatheter implantation has become
an attractive alternative. Several centers have published
results consistent with progressive reduction of
complications and mortality in selected patients [7,9,11,15].
In the selected cases for implantation on a failed
bioprosthesis, the results are even more encouraging,
since the risks of complications and possible
periprosthetic leaks are substantially smaller than the
implant when compared to a native valve, making it even
a more attractive alternative [9].
When compared to the implant on native prosthesis, it
is noteworthy that prior identification of prosthesis
dysfunction may be of extreme importance, since the same
nominal diameters vary by manufacturer and landmarks
chosen in the measurement. Moreover, radiological
identification is also quite variable, and may lead to difficulty
in precise location of the best implant site and the prosthetic
ring. Some devices also require radiopaque markers, making
the implant more dependent on the use of contrast media
and transesophageal echocardiography. In case of lack of
prior reliable information or unfavorable echocardiographic
windows, CT may play an important role in measuring the
annulus and collaborate to select the correct size of the
device to be implanted.
Hospital mortality of the procedure is quite variable in
the literature, but the groups, most often, are not
comparable. The observed risk is lower than predicted by
risk scores, although there are several questions about its
validity [16].
The overall mortality compared to the expected risk
scores demonstrates, again, that procedure is able to
provide additional benefits in terms of survival. Survival
after hospital discharge is also significant and causes of
mortality in evolution were not related to the prosthetic
device. Likewise, there was no structural degeneration of
implanted prostheses, although this segment is still short
for their definitive assessment [5].
The mean age of the study population is lower than
that found in other studies, however, it is noteworthy that
given the prevalence of rheumatic fever in the Brazilian
population the average age in the realization of the first
intervention is less. This fact explains why younger patients
had already undergone multiple prior surgeries, raising their
operative risk and justifying their inclusion in the study.
Complications occurred previously were not found in
this sample [17]. Failure to proper occlusion of the left
ventricular apex was not present. Some factors contribute
to this finding, as the learning curve and the presence of
adhesions that facilitate the support points and help the
apical occlusion.
There were no cases of need for renal replacement
therapy with hemodialysis, despite the presence of high
glomerular filtration rate below 50%. Possibly, the low use
of iodinated contrast collaborated to preserve renal
function.
In all cases, we used the apical via to the transcatheter
implant. The use of apical via, although more invasive, has
additional advantages: 1. The prosthesis positioning is
easier, given the proximity of the ventricular insertion point
and aortic ring 2. The crossing of the failed prosthesis using
guidewire and catheter insertion systems is easier, due to
its ventricular aspect, due to the position of the valve
leaflets; 3. The manipulation of the aortic arch is smaller,
reducing the possibility of stroke 4. Navigation through
the peripheral arterial system with the prosthesis is
unnecessary, possibly contributing to the reduction of
vascular complications.
Moreover, the presence of minithoracotomy certainly
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recommended for selected groups with contraindications
to the traditional procedure.
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